Biological effects of two antiretroviral tritherapy (stavudine-lamivudine-nevirapine and emitricitabine-tenofovir-efavirenz) in patients HIV positive in Abidjan (Côte d’Ivoire)

Paper Details

Research Paper 01/11/2015
Views (222) Download (3)

Biological effects of two antiretroviral tritherapy (stavudine-lamivudine-nevirapine and emitricitabine-tenofovir-efavirenz) in patients HIV positive in Abidjan (Côte d’Ivoire)

Tovi Wahon Marie Odile, Kouakou Koffi, Ouattara Fatou Shchérazade Epouse Soro, Abo Yao, Minga Albert
Int. J. Biosci.7( 5), 171-183, November 2015.
Certificate: IJB 2015 [Generate Certificate]


To better understand the effects of antiretroviral tritherapy on local population in Abidjan, a descriptive study was conducted on two therapeutic combinations (Stavudine-Lamivudine-Nevirapine and Emitricitabine-Tenofovir-Efavirenz). The patients studied were selected from people infected with HIV, who started treatment at National Center of Blood Donors in Abidjan, Côte d’Ivoire. These patients received regular treatment for 36 months, blood samples were taken every 6 months, clinical and laboratory assessments were performed. All patients were infected with HIV-1 type. Biological parameters analyzed showed positive impact of the treatment characterized by the increase of the number and the percentage of CD4+. The value of the number and the percentage of CD4 at the end of the treatment were around 400cells/mm3 and 35% respectively. The treatment did not show toxic effect on the liver and the kidney measured through the rate of creatinine, transaminases (TGO, TGP). The glycemy of the patients was normal without any significant modification. The clinical parameters confirm the positive impact of the treatment. Indeed, the Body Mass Index (BMI), the Brachial Perimeter (BP) and the Karnofsky Index (KI) were in the normal ranges. There is no significant difference between the two therapeutic combinations (Stavudine-Lamivudine-Nevirapine and Emtracitabine-Tenofovir-Efavirenz). These positive effects could explain the use of these therapeutic combinations in the first line treatment of HIV positive patients in the National centre of blood donors in Abidjan.


Agrawal S, Sawant S, Shastri J. 2010. Prevalence of HIV-2 infection in Mumbai. India Journal of Dermatology Venereology Leprology 76, 709-710.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D, Pediatric AIDS Clinical Trials Group 381 Study Team. 2008. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial non-suppressive highly active antiretroviral therapy. AIDS Patient Care STDS 22, 545-552.

Amadou A, Kouka N, Elhadj Mahamane A, Chanteau S. 2005. Evaluation de cinq tests rapides et de deux algorithmes pour le diagnosticde l’infection par le VIH au Niger. Bulletin de la Société de Pathologie Exotique 98(1), 5-8.

Barré-Sinoussi F, Mathur-Wagh U, Rey F, Brun-Vazinet F, Yancovitz SR, Rouzioux, Montagnier L, Mildvan D, Chermann JC. 1985. Isolation of lymphodenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS. Journal of American Medical Association 253, 1737-1739.

Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruet J, Dauguet C, Axler-Blin  C,  Vezinet-Brun  F,  Rouzioux  C, Rozenbaum W, Montagnier L. 1983. Isolation of a T-lymphotropic retrovirus from patient at risk of Acquired Immune Deficiency Syndrome (AIDS). Science 220, 868-871.

Basson AE. 2005. An investigation of plant extracts with HIV reverse transcriptase inhibitory activity. PhD in biochemistry, Rand Afrikaans University, South Africa, 141 pages.

Blanco JL, Varghese V, Rhee SY, Gatell GM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. Journal of Infectious Diseases 203, 1204-1214.

Chirouze C, Hoen B. 2006. Infection par le VIH. La révue du Praticien 56(9), 941-1012.

Crum-Cianflone NF, Tejidor R, Medina S, Barahona I, Ganesan A. 1992. Obesity among HIV patients : The latest epidemic. Infectious Diseases Society of America Annual Meeting, Oct. 4-7, San Diego. Final Program and Abstract. Abstract 888.

Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenverger S, Hertogs K. 2007. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. Journal of Virology 81, 13845-13851.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. 2002. Panel on clinical practices for treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Annals of International Medicine 137, 381-433.

Este JA, Cihlar T. 2010. Current status and challenges of antiretroviral research and therapy. Antiviral Research 85, 25-33.

Fener P. 2011. Traitement de l’infection à VIH : la restauration immunitaire comme objectif. Sida Sciences. (consulté le 16 avril 2014).

Fener P. 2011. Traitement de l’infection à VIH: la restauration immunitaire comme objectif. Sida Sciences.

Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto K, Miller MD. 2009. The triple combination of tenofovir, emtricitabine and efavirenz  shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6, 44.

Gervais A. 2009. Hépatotoxicité des antirétroviraux, John Libbey Eurotext (en ligne). Hépato-Gastro 16(2), 93-99.

Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Traore M, Sylla M, Calvez V, Marcelin AG. 2010. Level of viral load and antiretroviral resistance after 6 months of non-nucleotiside reverse transcriptase inhibitor first- line treatment in HIV-1 infected children in Mali. Journal of Antimicrobiology Chemotherapy 65(1), 118-124

Harmouche H, Le Bras Ph, Bignani O, Delfraissy JF, Goujard C. 2005. Insuffisance rénale aiguë avec diabète insipide et syndrome de Fanconi chez un patient infecté par le virus de l’immunodéficience humaine traité par Ténofovir. La Revue de Médecine Interne 26(6), 522-523.

Hofman P, Nelson AM. 2006. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Current Medical Chemistry 13, 3121-3132.

Izzedine H, Launay-Vacher V, Deray G. 2005. Antiviral drug-induced nephrotoxicity. American Journal of Kidney Diseases 45(5), 804-817.

Ji C, Kopetzki E, Jekle A, Stubenrauch KG, Liu X, Zhang J, Rao E, Schlothauer T, Fischer S, Cammack N, Heilek Ries S, Sankuratri S. 2009. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. Journal of Biological Chemistry 284, 5175-5185.

King RW, King K, Labe RM, Reid CD, Erickson Viitanen SK. 2002. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrobial Agents Chemotherapy 46, 1640-1646.

Kontorinis N, Dieterich D. 2003. Hepatotoxicity of antiretroviral therapy. AIDS 5(1), 36-43.

Krou PE, Yessé ZN, Kouadio IK, Kouamé P. 2012. Influence des Antirétroviraux (ARV) sur des paramètres biochimiques de quelques organes vitaux des personnes vivant avec le VIH en Côte d’Ivoire. Journal of Applied Biosciences 54, 3848-3858.

Lange J. 1995. Triple combinations: present and future. Journal of AIDS Human Retrovirology 10(Suppl 1), 77-82.

Lazon, Gange SJ, Wilson TE. 2007. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clinical infectious Disease 45, 1377-1383.

Leport C, Lootvoet E, Rossert J, Sobel A, Raffi F, Chêne G, le groupe d’étude APROCO-COPILOTE (ANRS CO8). 2014. Suivi à 7 ans de la fonction rénale des patients infectés par le VIH traits par antirétroviraux, cohorte ANRS CO8 COPILOTE. URL :,consultéle18février2014

Louie B, Wong E, Klausner JD, Liska S, Hecht F, Dowling T, Obeso M, Phillips SS, Pandori MW. 2008. Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals. Journal of clinical Microbiology, 1494-1497.

Miedema F. 2008. A brief history of HIV vaccine research: Stepping back to the drawing board. AIDS 22, 1699-1703.

Mitsuya H, Weinhold K, Furman P, St Clair M, Lehrman S, Gallo R, Bolognesi D, Barry D, Broder S. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proceed of National Academy of Science 82(20), 7096-7100.

Mocroft A, Kirt O, Barton ES, Dietrich M, Proenca R, Colebunders R. 1999. Anemia in an independent productive marker for clinical prognosis in HIV-infected patient from across Europe. AIDS 13, 943-950.

Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD. 2010. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24(11), 1667-1678.

Nkwanyana NN, Gumbi PP, Roberts L, Denny L, Hanekom W, Soares A, Allan B, Williamson A-L, Coetzee         D, Olivier AJ, Burgers WA, Passmore JA. 2009. Impact of human immunodeficiency virus 1 infecfion and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 128, 746-757.

Ollivon C. 2012. Surveillance hépatique chez les personnes vivant avec le VIH (PVVIH). infotraitements 212- mars-avril 2012.

Ondounda M, Tanon A, Ehui E, Ouattara I, Kassi A, Aba YT, Aoussi EF, Kakou AR, Eholié SP, Bissagnene E, Kadio A. 2010. Le syndrome de Fanconi induit par le ténofovir en Afrique : deux cas en Côte d’Ivoire ». Médecine et Maladies Infectieuses, édition en ligne du 15 Septembre 2010.

OMS. 2006. Traitement antiretroviral de l’infection à VIH chez l’adulte et l’adolescent en situation de ressources limitées : vers un accès universel. Récommandations pour une approche de santé publique. Organisation Mondiale de la Santé, Département VIH/SIDA, Génève, Suisse, 132 pages.

ONUSIDA. 2009. Programme National de Prise en charge Médicale des Personnes Vivant avec le VIH/SIDA. Rapport sur l’épidémie mondiale du sidaen 2009.

Pavie J, Rachline A, Loze B, Niedbalski L, Delaugerre C, Laforgerie E, Plantier JC, Rozenbaum W, Chevret S, Molina JM, Simon F. 2010. Sensitivity of fire rapid HIV test on oral fluid or finger-stick whole blood: A real-time comparison in a healthcare setting. PlosOne 5(7), 1-7.

Podsadecki T, Vrijens B, Tousset E. 2007. Decrease adherence to antiretroviral therapy observed prior to transient human immunodeficienty virus type 1 viremia. Journal of Infectious Disease 196, 1773-1785.

Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. 2012. Association of Tenofovir exposure with kidney disease risk in HIV infection. AIDS 26, 867–875.

TEMPRANO-ANRS 12136 trial. 2010. Bénéfices et risques du traitement ARV précoce et prévention par INTI chez des adultes infectés par le VIH ayant entre 250 et 500 CD4/mm3 : à Abidjan, côte d’Ivoire. Etat d’avancement, INSERM, Unité 897, Programme PAC-CI, Abidjan, Côte d’Ivoire.

Tovi Wahon Marie Odile, Ouattara Fatou Shcherazade Epouse Soro, Abo Yao, Minga Albert, Kouakou Koffi. 2014. Biological effects of antiretroviral drugs in patients VIH positive of the national centre of blood donors in Abidjan (Cote d’Ivoire): gender and age groups analysis. International Journal of Biosciences 4(9), 272-281.

Traba-Villameytide ML, Fernandez-Guerrero M. 2004. Idinavir and renal lithiasis ». Actas Urol Esp 28(7), 523-526.

Vahlne A. 2009. A historical reflection on the discovery of human retroviruses. Retrovirology 6, 40-40.

Van der Sande MAB, Van der Loeff MFS, Aveika AA, Sabally S, Togun T, Sarge-Njie, Alabi AS, Jaye A, Corrah T, Whittle HC. 2004. Body mass Index at time of HIV diagnosis a strong and independent predictor of survival. Journal of Acquired Immune Deficiency Syndrome 37(2), 1288-1294.

Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1(8481), 575-580.